[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] European Association For The Study Of The Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
[3] Marrero J A, Kulik L M, Sirlin C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68(2): 723-750.
[4] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2017, 389(10064): 56-66.
[5] Abou-Alfa G K, Meyer T, Cheng A L, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. J Clin Oncol, 2018, 36: 94.
[6] El-Khoueiry A. The promise of immunotherapy in the treatment of hepatocellular carcinoma. ASCO Educational Book, 2017, 37: 311-317.
[7] Wang H, Liu A, Bo W, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Dig Liver Dis, 2016, 48(11): 1275-1282.
[8] Meng Y, Yu Z, Wu Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application. Hum Vacc Immunother, 2017, 13(6): 1379-1387.
[9] Lee J H, Lee J H, Lim Y S, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 2015, 148(7): 1383-1391.
[10] Xu L, Wang J, Kim Y, et al. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology, 2016, 5(3): e1083671.
[11] Lee J H, Tak W Y, Lee Y, et al. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology, 2017, 6(7): e1328335.
[12] Kaseb A O, Carmagnani Pestana R, Vence L M, et al. Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. J Clin Oncol, 2019, 37(4):185.
[13] Duffy A G, Ulahannan S V, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol, 2017, 66(3): 545-551. |
